Hospital
Swisher Memorial Healthcare System
Swisher Memorial Healthcare System was paid $360K by Medicaid between Jan 2021 and Nov 2024, across 14 billing codes. Its largest line is 87633, Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets — 62% of everything it billed.
33Billing provider infoSWISHER MEMORIAL HEALTHCARE SYSTEM
TULIA, TX 79088
TULIA, TX 79088
33aNPI1518253194assigned 06/22/2011
33bProvider typeCritical Access Hospital
28Total paid$360K
24GClaims3,088
24DCodes billed14
24AFirst – last monthJan 2021 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in Texas
Rank by total paid#19 of 47
Median peer was paid$170K
This provider vs. median2.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 1,137 | $54K | |
| 2022 | 976 | $60K | |
| 2023 | 574 | $132K | |
| 2024incomplete | 401 | $113K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 62% | 378 | 371 | $224K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 8.8% | 512 | 496 | $32K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.8% | 114 | 107 | $21K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 5.2% | 306 | 300 | $19K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3.7% | 727 | 701 | $13K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.3% | 38 | 37 | $12K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 3.3% | 14 | 14 | $12K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 3.2% | 482 | 465 | $11K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.9% | 336 | 160 | $11K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.0% | 57 | 57 | $4K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 40 | 36 | $789.83 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15 | 14 | $736.64 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBREWER, LUCAS (CEO)